Systemic and central haemodynamics were evaluated in 10 lean and 10 obese hypertensive patients (World Health Organization stage I – II) after treatment for 8 weeks with a serotoninergic antagonist, such as ketanserin. Blood pressure and heart rate were recorded and first-pass radionuclide angiocardiography was performed to determine cardiac output, cardiac index and ejection fraction of the left ventricle; total peripheral resistance was also calculated. In both obese and lean patients, ketanserin significantly reduced diastolic (P < 0.05) and mean (P < 0.005) blood pressure but no significant changes in systolic blood pressure, cardiac output, cardiac index and ejection fraction were observed in lean and obese hypertensive patients. Total peripheral resistance was significantly (P < 0.05) reduced in lean patients but in obese hypertensives it was only moderately reduced. It is concluded that monotherapy with ketanserin is effective in treating mild to moderate hypertension in both lean and obese hypertensive patients, without interfering with left ventricular performance.
Lund-JohansenP: State of the art review: haemodynamics in essential hypertension. Clin Sci1980; 59: 3430–3434.
2.
VanhouttePM: Peripheral serotoninergic receptors and hypertension. In: Serotonin and the Cardiovascular System (VanhouttePM, ed). New York: Raven Press, 1985; pp 123–133.
3.
De CreeJ, LempoelsJ, GeukensH, Are serotoninergic mechanism involved in high blood pressure. In: 5-Hydroxytryptamine in Peripheral Reactions (De ClerckF, VanhouttePM, eds). New York: Raven Press, 1982; pp 183–192.
4.
BlackshearJL, OrlandiC, GarnieJD, Differential large and small vessels responses to serotonin in the dog hindlimb in vivo: role of the 5-HT, receptor. J Cardiovasc Pharmacol1985; 7;42–49.
5.
PeroukaSJ, SnyderS: Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and spiroperidol. Mol Pharmacol1979; 16: 687–699.
6.
VanhouttePM: 5-Hydroxytryptamine, vasospasm and hypertension. In: 5-Hydroxytryptamine in Peripheral Reactions (De ClerckF, VanhouttePM, eds). New York: Raven Press, 1982; pp 163–174.
LeysenJE, AwoutersF, KennisL: Receptor binding profile of R-41468, a novel antagonist at 5-HT2 receptors. Life Sci1981; 28: 1015–1022.
9.
MarwoodJF, StokesGS: Studies on the mechanism of the action of the hypotensive effect of ketanserin. Clin Exp Pharmacol Physiol1984; 11: 125–132.
10.
AndrenL, SvenssonA, DahlorB: Ketanserin in hypertension. Acta Med Scand1983; 214: 125–130.
11.
De ClerckF, JagenawA, DomJ: Haemorheological effects of ketanserin, a selective 5-HT receptor antagonist in aged spontaneously hypertensive dogs. Arch Int Pharmacodyn Ther1982; 285: 110–115.
12.
PettersonA, PerssonB, HemingM: Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT) receptor blockade with ketanserin in the spontaneously hypertensive rat. Arch Pharmacol1984; 327: 43–47.
13.
CameronMA, RamsayLE: Ketanserin in essential hypertension: a double-blind, placebo-controlled study. Postgrad Med J1985; 61: 583–586.
14.
McGourtyJC, SilasJH, CowenKJ: Controlled trial of ketanserin in hypertension. Br J Clin Pharmacol1985; 20: 37–40.
15.
PalermoA, MaraG, PizzaN: Clinical experience with ketanserin in the treatment of hypertension. J Hypertens1986; 4 (suppl 1): S81–S83.
16.
KirckW, OhnhausE: Double-blind comparison of ketanserin with atenolol: antihypertensive activity and effect on platelet function. J Hypertens1986; 4 (suppl 1): S67–S71.
17.
HednerT, PerssonB, BerglundC: A comparative and long term evaluation of ketanserin in the treatment of essential hypertension. J Cardiovasc Pharmacol: 1985; 7 (suppl 7): S148–S153.
18.
Beretta-PiccoliC, AmstenR, BertelO: Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss ketanserin study. J Cardiovasc Pharmacol1987; 10 (suppl 3): S107–S112.
19.
HannedoucheT, FillastreJP, MihranA: Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicentre study. J Cardiovasc Pharmacol1987; 10 (suppl 3): S107–s112.
20.
RosenthalJ, KoehleW, GruebelB: Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker. J Hypertens1986; 4 (suppl 1): S85–S87.
21.
ChiangBN, PerlmanLV, EpsteinFH: Overweight and hypertension. Circulation1969; 39: 403–421.
22.
StamlerR, StamlerJ, RiedlingerWF: Weight and blood pressure: findings in hypertension screening of 1 million Americans. JAMA1978; 240: 1607–1612.
23.
DondersSHJ, PietersGFM, HeebelLG: Disparity of thyrotropin (TSH) and prolactin responses to TSH releasing hormone in obesity. J Clin Endocrinol Metab1985; 61: 56–59.
24.
GarrowJJ, WebsterJ: Quentelet's index (W/H2) as a measure of fatness. Int J Obes1985; 9: 147–153.
25.
LicataG, IndovinaA, NovoS: Studio della funzione ventricolare sinistra eseguito con la ventricolografia radioisotopica al primo passaggio. Cardiologia1984; 29: 615–636.
26.
VenkataC, GonzalezDG, KaplanNM: Renal hemodynamic effects of ketanserin therapy in essential hypertension. J Cardiovasc Pharmacol1987; 10 (suppl 3); S78–S80.
27.
CasigliaE, GavaR, NicholinP: Effetto ipotensivo della ketanserina e valutazione dell‘ attività alfabloccante. Cardiologia1986; 31: 1709–1714.
28.
SymoensJ, JanssensM: Ketanserin: a novel cardiovascular drug. Drugs Dev Res1986; 8: 159–172.
29.
BreckenridgeA: Ketanserin, a new antihypertensive agent. J Hypertens1986; 4 (suppl 1): S13–S16.
30.
MesserliFH, ChristieB, De CarvalhoJGR: Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion and plasma renin activity. Arch Intern Med1981; 141: 81–85.
31.
CohenML, FullerRW, KurzKD: Evidence that blood pressure reduction by serotonin antagonists is related to alpha-receptor blockade in spontaneously hypertensive rats. Hypertension1983; 5: 676–681.
32.
SanchezRA, OteroF, RamirezA: Analysis of left ventricular function by radionuclide ventriculography in patients with essential hypertension treated with ketanserin. J Hypertens1986; 4 (suppl 6): S119–S121.
33.
ZanchettiA: Serotonin and cardiovascular regulation: a new approach to hypertension. J Hypertens1986; 4 (suppl 1): S37–S38.
